Controversy Surrounding E-Cigarettes as Smoking Cessation Tool

Jan.10.2023
Controversy Surrounding E-Cigarettes as Smoking Cessation Tool
A study claims e-cigarettes do not help smokers quit, but experts criticize its design and potential bias.

In December of last year, the UK's Office for National Statistics (ONS) confirmed the "key role" that e-cigarettes have played in driving smoking rates in the country to their lowest point in history. However, a study published in the Tobacco Control journal shortly after claims that e-cigarettes are not effective tools for quitting smoking. This report has come under criticism from experts and the UK Vaping Industry Association (UKVIA).


This study has sparked a headline in the Daily Mail claiming "study finds e-cigarettes cannot help people quit regular cigarettes." The headline came just seven days after the UK encouraged smokers to switch to e-cigarettes as a means of quitting traditional smoking.


A record-breaking 4 million people in the UK are now using electronic cigarettes, according to the UK National Statistics Office. This widespread shift towards e-cigarettes is believed to be partially responsible for a decrease in the smoking rate in the UK to just 13.3% - the lowest recorded figure to date.


Professor Peter Hajek from Queen Mary University of London states that the conclusion 'e-cigarettes have not made a significant contribution to smoking cessation among the population' cannot be drawn from the available data.


A new study from George Washington University in the United States focuses on "dual users" - people who smoke cigarettes and use electronic cigarettes. The study analyzed data from 2013 to 2019 and concluded that "before 2019, the use of electronic nicotine delivery systems (ENDS) did not contribute to substantial smoking cessation at the population level.


The authors of the study stated that their findings "suggest that reducing smoking can help dual users quit using both products," but critics argue that the study has limitations.


Dr. Sarah Jackson, Head Researcher of the Tobacco and Alcohol Research Group at University College London (UCL), stated that this study did not assess whether or not e-cigarettes help smokers quit smoking.


To determine whether using electronic cigarettes can help people quit smoking, we need to study the difference in smoking cessation rates between users of electronic cigarettes and non-users.


Other studies have already done so, using observational and experimental research designs, and indicate that smokers who attempt to quit smoking using e-cigarettes are more likely to succeed.


The UKVIA believes that vaping can aid smokers in quitting | Source: moffitt.org


Professor John Britton, esteemed epidemiologist at the University of Nottingham, stated, "The design of this study selected individuals who either found it difficult to quit smoking or did not want to quit. In this scenario, the good news is that some individuals were able to achieve success.


This study cannot tell us whether smokers who become dual users are more successful at quitting smoking than smokers who do not become dual users.


Therefore, the message of this paper is that quitting smoking is very difficult, but using electronic cigarettes may help you achieve it. Saying that e-cigarettes can stop you from quitting smoking in the "real world" is incorrect.


Peter Hajek, the director of the Tobacco Dependence Research Unit at Queen Mary University of London, stated that the conclusion that "e-cigarettes make no significant contribution to people quitting smoking" cannot be drawn from the data.


This study focused only on individuals who did not quit smoking and became "dual users" of e-cigarettes, excluding those who quit smoking altogether. Despite the selection of individuals who did not immediately receive full benefits, more than 25% of dual users actually quit smoking.


Excluding those who completely switch to using e-cigarettes and only evaluating their effectiveness on those who become dual users presents a serious methodological problem. It is like picking the best apples from a fertilized orchard, measuring the remaining apples, and declaring that the fertilizer is ineffective.


The tobacco control press release is particularly misleading. It claims that dual use is harmful, but in reality it is associated with reduced smoking and subsequent smoking cessation, making it actually beneficial. It also asserts that the study found e-cigarettes do not help smokers quit more easily, but the paper did not make such a statement.


Professor Robert West, Honorary Professor of Health Psychology at University College London, stated that "this study cannot resolve whether e-cigarettes at a population level help or hinder smoking cessation, but this conclusion may be temporary - so it is surprising to see such a statement from a reputable scientific journal.


A recent study on population trends reveals that individuals attempting to quit smoking are more likely to succeed if they use electronic cigarettes. Moreover, the increasing use of electronic cigarettes in the population is positively correlated with an increase in successful attempts to quit smoking over time.


This confirms strong evidence from randomized trials in which smokers were randomly assigned to receive either electronic cigarettes or products such as nicotine patches, gum, and lozenges. These studies clearly demonstrate that electronic cigarettes are superior.


The press release claims that data suggests the use of e-cigarettes may not be helpful in aiding a sample population to quit smoking, which is particularly surprising given that at the start of the research, individuals who used e-cigarettes daily were more likely to quit smoking in the following two years compared to non-daily users. This is contrary to the direction they seem to be asserting.


John Dunne, the Director General of UKVIA, stated, "No wonder smokers are feeling confused when faced with such mixed messages.


At a recent vaping summit in London, Rosanna O'Connor from the Health Improvement and Differentiation Office advised attendees not to always trust what they read in the media. I fully agree with her statement.


When the same newspaper tells you one day how e-cigarettes can help people quit smoking in the UK, and then contradicts itself the next day, it may seem amusing, but there is a serious point to be made here.


Misinformation about e-cigarettes has prevented smokers from switching to e-cigarettes, which in turn means that lives will continue to be unnecessarily lost due to deadly combustible cigarettes.


When the UK Office for National Statistics expresses enough confidence to say that electronic cigarettes have played a "major role" in reducing smoking rates in the UK, we can be certain that this is true.


If anyone truly doubts whether e-cigarettes can really help people quit smoking, they can ask any of the country's four million e-cigarette users for their thoughts!



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
SnowPlus has introduced a nicotine-free version of DASH in South Korea, adapting an existing overseas disposable platform for the local market. The Korean version retains the series’ flat duckbill-style mouthpiece, ceramic heating architecture and disposable form factor while reducing nicotine content to 0%. By comparison, the overseas DASH 4000 platform typically features 7.5ml of prefilled e-liquid, up to 4,000 puffs and a 530mAh rechargeable battery, with nicotine-containing variants available in some markets. The product update centers on formulation localisation rather than a new hardware generation.
Aug.31
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
Philip Morris International's PMI Business Solutions Philippines has expanded its global business services hub in Makati and plans to add more than 80 positions. Established in 2021 primarily to provide finance and IT support to about 20 markets, the center now employs 519 professionals delivering roughly 600 services across 160 markets. Its functions now span finance, human resources, IT, commercial operations, data analytics, supply chain and project management. PMI says the hub's next phase will focus on AI-enabled and higher-value work. The company did not disclose the size or investment cost of the expansion.
Sep.24
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09